Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dipraglurant - Addex Therapeutics

Next Previous
X
Search
Drug Profile

Dipraglurant - Addex Therapeutics

Alternative Names: ADX-48621; Dipraglurant-ER; Dipraglurant-IR; mGluR5-NAM

Latest Information Update: 30 May 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Alkynes; Antidepressants; Anxiolytics; Heterocyclic bicyclo compounds; Imidazoles; Muscle relaxants; Neuropsychotherapeutics; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Drug-induced dyskinesia
  • Phase II Blepharospasm; Torticollis
  • Preclinical Stroke
  • No development reported Major depressive disorder
  • Discontinued Anxiety disorders

Most Recent Events

  • 23 May 2024 Addex Therapeutics has patents pending for Dipraglurant composition of matter and its polymorphs
  • 23 May 2024 Addex Therapeutics has patent protection for Dipraglurant composition of matter and its polymorphs in the US, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Macedonia, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Liechtenstein, Turkey, Australia, Brazil, Canada, China, Hong Kong, Indonesia, Israel, Japan, South Korea, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and Ukraine
  • 10 Aug 2023 Addex Therapeutics plans a phase II trial for Stroke (PO) in 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top